This document provides a COVID-19 situation report for the Philippines as of January 10, 2022. Key details include:
- There were 128,114 active COVID-19 cases as of January 9, with the majority (93.1%) being mild cases and 4,213 asymptomatic cases.
- The top regions by new cases were NCR, CALABARZON, and Central Luzon.
- The daily positivity rate for tests conducted on January 9 was 44.01% and the estimated reproduction number (Rt) was 2.745, suggesting increasing transmission.
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...JohnJulie1
This study analyzed 261 asymptomatic patients who were screened for COVID-19 via PCR testing prior to planned procedures or surgeries in July 2020. The screening found that 6 patients (2.29%) tested positive for COVID-19 and had to delay or cancel their procedures. Screening asymptomatic patients is important to prevent potential spread of the virus to healthcare workers and other patients. While PCR testing has limitations, it remains the best method for diagnosing COVID-19 infection. Screening all patients prior to elective medical care is recommended to protect patient and provider safety during the ongoing pandemic.
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...suppubs1pubs1
The current pandemic of Corona Virus Disease-2019 (COVID-19) which is caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) has resulted in lockdown in many countries culminating in a major socio-economic crisis globally. COVID-19 can remain asymptomatic and so is crucial for early diagnosis to prevent further spread of this pandemic. Here we highlight the importance of screening asymptomatic patients prior to elective surgery, procedure or scheduled hospital admission. This analysis was done for the month of July 2020 during which 261 asymptomatic people were screened for COVID-19. Out of this, 6 patients (2.29%) were diagnosed to have COVID-19 on nasopharyngeal/ oropharyngeal swabs and subsequently had to delay their elective procedure or surgery. This clearly shows how important it is to screen this cohort of asymptomatic people who could potentially have spread the virus to other patients as well as healthcare professionals.
Health Advances Demystifying COVID Testing - 4th Edition.pdfHealth Advances
• As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future.
Health Informatics - Transforming healthcare delivery in Hong Kong. Presented by Dr Ngai-Tseung Cheung, Head of Information Technology and Health Informatics/Chief Medical Informatics Officer, Hong Kong Hospital Authority, at HINZ 2014, 11 November 2014, 9.15am, Plenary Room
The document summarizes a Centers for Disease Control and Prevention presentation on the monkeypox outbreak. It provides updates on epidemiology, testing, treatment with tecovirimat, and vaccination efforts. As of July 25, there were over 3,000 cases reported in the US. Testing capacity is over 80,000 tests per week through commercial and public health laboratories. Treatment guidance for tecovirimat through an expanded access protocol has been streamlined.
This is a lecture I gave for the Upstate Nurse Practitioner's Association September 29, 2020. Parts may no longer be valid, because the topic is changing so rapidly. I did the best I could.
This was a lecture I gave for the Upstate Nurse Practitioners Association. This is a comprehensive overview. I would to thank all health care professionals for doing their jobs as well as they can.
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...JohnJulie1
This study analyzed 261 asymptomatic patients who were screened for COVID-19 via PCR testing prior to planned procedures or surgeries in July 2020. The screening found that 6 patients (2.29%) tested positive for COVID-19 and had to delay or cancel their procedures. Screening asymptomatic patients is important to prevent potential spread of the virus to healthcare workers and other patients. While PCR testing has limitations, it remains the best method for diagnosing COVID-19 infection. Screening all patients prior to elective medical care is recommended to protect patient and provider safety during the ongoing pandemic.
Should All Patients Having Planned Procedures or Surgeries Be Tested for COVI...suppubs1pubs1
The current pandemic of Corona Virus Disease-2019 (COVID-19) which is caused by Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) has resulted in lockdown in many countries culminating in a major socio-economic crisis globally. COVID-19 can remain asymptomatic and so is crucial for early diagnosis to prevent further spread of this pandemic. Here we highlight the importance of screening asymptomatic patients prior to elective surgery, procedure or scheduled hospital admission. This analysis was done for the month of July 2020 during which 261 asymptomatic people were screened for COVID-19. Out of this, 6 patients (2.29%) were diagnosed to have COVID-19 on nasopharyngeal/ oropharyngeal swabs and subsequently had to delay their elective procedure or surgery. This clearly shows how important it is to screen this cohort of asymptomatic people who could potentially have spread the virus to other patients as well as healthcare professionals.
Health Advances Demystifying COVID Testing - 4th Edition.pdfHealth Advances
• As we enter the endemic phase of COVID-19, we wanted to share our final edition of Demystifying COVID-19 Testing. In this edition, we provide an update on testing dynamics and share our assessment of the impact on the industry and our predictions for the future.
Health Informatics - Transforming healthcare delivery in Hong Kong. Presented by Dr Ngai-Tseung Cheung, Head of Information Technology and Health Informatics/Chief Medical Informatics Officer, Hong Kong Hospital Authority, at HINZ 2014, 11 November 2014, 9.15am, Plenary Room
The document summarizes a Centers for Disease Control and Prevention presentation on the monkeypox outbreak. It provides updates on epidemiology, testing, treatment with tecovirimat, and vaccination efforts. As of July 25, there were over 3,000 cases reported in the US. Testing capacity is over 80,000 tests per week through commercial and public health laboratories. Treatment guidance for tecovirimat through an expanded access protocol has been streamlined.
This is a lecture I gave for the Upstate Nurse Practitioner's Association September 29, 2020. Parts may no longer be valid, because the topic is changing so rapidly. I did the best I could.
This was a lecture I gave for the Upstate Nurse Practitioners Association. This is a comprehensive overview. I would to thank all health care professionals for doing their jobs as well as they can.
The document provides information on the novel coronavirus (2019-nCoV) including its transmission, clinical features, case definitions, personal protective equipment guidelines, and recommendations for self-quarantine. It aims to guide healthcare workers in Sri Aman, Malaysia on preparing for and responding to potential cases of the novel coronavirus.
Baseline characteristics and outcomes of 1591 patients infected with sars co ...Valentina Corona
This case series describes 1591 critically ill patients with COVID-19 admitted to ICUs in Lombardy, Italy between February 20th and March 18th. The median age was 63 years and 82% were male. Of those with available data, 68% had at least one comorbidity and 49% had hypertension. Among those with respiratory support data, 99% required support including 88% who received mechanical ventilation. ICU mortality was 26% as of March 25th and older patients had higher mortality than younger patients.
This study analyzed the impact of the COVID-19 pandemic on pediatric surgical care at a single center in Bangalore, India. The authors compared data from before the pandemic (September 2019-March 2020) to after (October 2020-April 2021). They found significant declines in both elective and emergency pediatric surgeries performed, as well as outpatient visits. Protocols were established for screening and treating COVID-19 positive patients requiring surgical care. The pandemic disrupted pediatric surgery practices and increased hospital stays. It also reduced emergency case volumes, a concern. Overall, the study shows how the pandemic severely affected pediatric surgical services at this hospital in India.
Keberhasilan Selandia Baru dalam mengatasi penyebaran Covid-19 pada gelombang pertama menjadi pelajaran berharga bagi negara-negara di seluruh dunia dalam merancang sebuah strategi kebijakan mengatasi Covid-19
The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were
tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results.
Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the
CareStart™ COVID-19 Antigen.
High-dose Hook Effect
The CareStart™ COVID-19 Antigen was tested up to 105 TCID50/ml of heat-inactivated SARSCoV-2 strain and no high-dose hook effect was observed.
Point of Care Use
The CareStart™ COVID-19 Antigen was demonstrated at near patient or Point of Care (POC)
testing that non-laboratory personnel can perform the test accurately in the intended use
environment. In addition, the robust use of the CareStart™ COVID-19 Antigen for near patient
or Point of Care (POC) testing was demonstrated by thirteen (13) Flex studies.
Technical Support
For questions, or to report a problem, please call Technical Support at +1-888-898-1270
(Available Hours: Mon. to Fri.: 8 a.m. – 5 p.m.) or TShelp@accessbio.net (24/7 available).
Test system problems may also be reported to the FDA using the MedWatch reporting system
(phone: 1-800 FDA-1088; fax: 1-800 FDA-1078: or http://www.fda.gov/medwatch)
For Emergency Use Authorization (EUA) Only
The CareStartTM COVID-19 Antigen test is a lateral ow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2
in nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within ve days of symptom onset.
IMPORTANT!
- Refer to the Package Insert for Warnings and Precautions, Specimen Collection Procedures, Storage and Handling Conditions, and Quality Control Recommendations.
- Warning and Precautions - All kit components can be discarded as Biohazard waste according to local guidelines. Refer to the product safety data sheet for risk and safety phrases and disposal information.
- Biotin Interference: False negative results may occur in patients who have indicated or whose clinical status or history would indicate they are currently taking high doses of biotin (> 10 mg per day). Biotin
levels of 2.5 µg/mL have been demonstrated to result in false negative test results.
- The extracted sample must be used within 4 hours of preparation when stored at room temperature.
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html
Mr. Shatrughan Pareek presented on nurses serving as "soldiers of COVID-19". He discussed the introduction and spread of COVID-19 globally and in India. Nurses play important roles in communities by raising awareness and supporting surveillance, and in clinical settings by safely assessing, treating, and caring for patients with respect and confidentiality. While being on the frontlines carries risks of infection, it also brings professional growth and social appreciation. Various policies have both positively impacted nurses through insurance and PPE, and negatively through lack of facilities and financial losses.
This document provides information on the global epidemiology and transmission of COVID-19. It discusses trends in cases and deaths globally and in the US. It reviews proposed routes of transmission, including via aerosols, droplets, fomites, and the environment. The viability of SARS-CoV-2 on different surfaces is summarized. Prevention strategies like hand washing, social distancing and face coverings are also covered.
Risk management covid by zurinoor (ESC 5113)TengkuIsmail2
The document discusses the COVID-19 situation in Malaysia, globally, and some other countries. It outlines the phases and movement control orders Malaysia implemented. Current statistics in Malaysia show over 8,500 total cases. New clusters were detected during the recovery movement control order phase. The document also discusses the increasing numbers seen in the United States, India, Brazil, Indonesia, and Singapore. It concludes by emphasizing the importance of following safety procedures until a vaccine is developed.
CDC dec 2015 - Strengthening a Culture of Laboratory SafetyMark Lacic
The document discusses the history and evolution of laboratory science and safety standards at the Centers for Disease Control and Prevention (CDC). It describes how CDC laboratories have grown from focusing on malaria and communicable diseases to encompassing over 150 laboratory groups conducting research on infectious diseases, environmental health, and more. It summarizes changes made at CDC in response to safety incidents in 2014, including establishing new laboratory leadership and revising risk assessment processes.
The coronavirus pandemic of 2019–2020 is an infectious disease caused by extreme acute respiratory coronavirus syndrome 2 (SARS‐CoV‐2). The virus primarily spread among people when they closely meet each other. Due to the decreased immune-compromised state, cancer patients are at high risk. Through this whitepaper, we have enlighted about the effect of the COVID-19 on cancer patients.
Paul E. Sax, MD prepared useful Practice Aids pertaining to COVID-19 for this CME/MOC/CNE/CPE activity titled "Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at https://bit.ly/3gBvfOw. CME/MOC/CNE/CPE credit will be available until July 23, 2021.
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Mass general covid 19 treatment guideline july012020Adiel Ojeda
This document provides guidance for clinicians at Massachusetts General Hospital (MGH) on the treatment of COVID-19. It summarizes recommended diagnostic testing and risk stratification for hospitalized patients. It also provides guidance on therapeutic considerations, including anti-infectives, cardiovascular medications, antithrombotics, and COVID-19 specific treatments such as remdesivir. The document is regularly updated as new data emerges on the management of COVID-19.
This document summarizes information from Dr. Tahseen J. Siddiqui on COVID-19. It discusses the three known coronaviruses that cause SARS, MERS, and COVID-19. It emphasizes that mitigation through strict social isolation is the best current strategy to slow transmission rates and prevent healthcare systems from being overwhelmed. The risks of personal infection are low but systemic risks are high if many require critical care simultaneously. Early action through testing, contact tracing, and quarantines have helped countries like Taiwan better control the spread.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
This document provides an overview of COVID-19 including its timeline, transmission, presentation, epidemiology, prevention, and containment plan. It discusses that COVID-19 is a respiratory infection caused by SARS-CoV-2. It outlines the timeline of the outbreak beginning in December 2019 in Wuhan, China. It also discusses transmission modes, signs and symptoms, disease progression, prevention strategies like isolation, quarantine, hand hygiene, and use of personal protective equipment.
This document provides information on the 2019 novel coronavirus (COVID-19) outbreak, including that it originated from Wuhan, China in December 2019 and is transmitted between humans. It causes respiratory illness with common symptoms like fever, cough and fatigue. While most cases are mild, management involves early detection, infection control measures, and supportive care like oxygen therapy for severe cases.
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by...HK HuZef
The document provides instructions for using the CareStart COVID-19 Antigen rapid diagnostic test. It is a lateral flow test intended to qualitatively detect SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swabs. The test involves extracting the swab in buffer, adding drops of extracted sample to the test cassette, and reading results at 10 minutes. Positive results require lines in both the test and control lines, while negative results have only a control line.
Dr Jennifer Njenga from Canada Home Care Group spent an hour teaching and educating us on the topic Vaccines and You. She covered myths about the vaccines and why you must take the second dose.
Researchers at the Network Dynamics and Simulation Science Laboratory have been using a combination of modeling techniques to predict the spread of the Ebola outbreak.
The document provides information on the novel coronavirus (2019-nCoV) including its transmission, clinical features, case definitions, personal protective equipment guidelines, and recommendations for self-quarantine. It aims to guide healthcare workers in Sri Aman, Malaysia on preparing for and responding to potential cases of the novel coronavirus.
Baseline characteristics and outcomes of 1591 patients infected with sars co ...Valentina Corona
This case series describes 1591 critically ill patients with COVID-19 admitted to ICUs in Lombardy, Italy between February 20th and March 18th. The median age was 63 years and 82% were male. Of those with available data, 68% had at least one comorbidity and 49% had hypertension. Among those with respiratory support data, 99% required support including 88% who received mechanical ventilation. ICU mortality was 26% as of March 25th and older patients had higher mortality than younger patients.
This study analyzed the impact of the COVID-19 pandemic on pediatric surgical care at a single center in Bangalore, India. The authors compared data from before the pandemic (September 2019-March 2020) to after (October 2020-April 2021). They found significant declines in both elective and emergency pediatric surgeries performed, as well as outpatient visits. Protocols were established for screening and treating COVID-19 positive patients requiring surgical care. The pandemic disrupted pediatric surgery practices and increased hospital stays. It also reduced emergency case volumes, a concern. Overall, the study shows how the pandemic severely affected pediatric surgical services at this hospital in India.
Keberhasilan Selandia Baru dalam mengatasi penyebaran Covid-19 pada gelombang pertama menjadi pelajaran berharga bagi negara-negara di seluruh dunia dalam merancang sebuah strategi kebijakan mengatasi Covid-19
The interfering effects of biotin concentrations ranging between 625 ng/mL and 10 µg/mL were
tested in a separate study. Biotin concentrations up to 1.25 µg/ml did not lead to false results.
Biotin concentrations ≥2.5 µg/ml can cause false-negative COVID-19 results with the
CareStart™ COVID-19 Antigen.
High-dose Hook Effect
The CareStart™ COVID-19 Antigen was tested up to 105 TCID50/ml of heat-inactivated SARSCoV-2 strain and no high-dose hook effect was observed.
Point of Care Use
The CareStart™ COVID-19 Antigen was demonstrated at near patient or Point of Care (POC)
testing that non-laboratory personnel can perform the test accurately in the intended use
environment. In addition, the robust use of the CareStart™ COVID-19 Antigen for near patient
or Point of Care (POC) testing was demonstrated by thirteen (13) Flex studies.
Technical Support
For questions, or to report a problem, please call Technical Support at +1-888-898-1270
(Available Hours: Mon. to Fri.: 8 a.m. – 5 p.m.) or TShelp@accessbio.net (24/7 available).
Test system problems may also be reported to the FDA using the MedWatch reporting system
(phone: 1-800 FDA-1088; fax: 1-800 FDA-1078: or http://www.fda.gov/medwatch)
For Emergency Use Authorization (EUA) Only
The CareStartTM COVID-19 Antigen test is a lateral ow immunochromatographic assay intended for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2
in nasopharyngeal swab specimens directly collected from individuals who are suspected of COVID-19 by their healthcare provider within ve days of symptom onset.
IMPORTANT!
- Refer to the Package Insert for Warnings and Precautions, Specimen Collection Procedures, Storage and Handling Conditions, and Quality Control Recommendations.
- Warning and Precautions - All kit components can be discarded as Biohazard waste according to local guidelines. Refer to the product safety data sheet for risk and safety phrases and disposal information.
- Biotin Interference: False negative results may occur in patients who have indicated or whose clinical status or history would indicate they are currently taking high doses of biotin (> 10 mg per day). Biotin
levels of 2.5 µg/mL have been demonstrated to result in false negative test results.
- The extracted sample must be used within 4 hours of preparation when stored at room temperature.
- Refer to the CDC Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19)
https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html
Mr. Shatrughan Pareek presented on nurses serving as "soldiers of COVID-19". He discussed the introduction and spread of COVID-19 globally and in India. Nurses play important roles in communities by raising awareness and supporting surveillance, and in clinical settings by safely assessing, treating, and caring for patients with respect and confidentiality. While being on the frontlines carries risks of infection, it also brings professional growth and social appreciation. Various policies have both positively impacted nurses through insurance and PPE, and negatively through lack of facilities and financial losses.
This document provides information on the global epidemiology and transmission of COVID-19. It discusses trends in cases and deaths globally and in the US. It reviews proposed routes of transmission, including via aerosols, droplets, fomites, and the environment. The viability of SARS-CoV-2 on different surfaces is summarized. Prevention strategies like hand washing, social distancing and face coverings are also covered.
Risk management covid by zurinoor (ESC 5113)TengkuIsmail2
The document discusses the COVID-19 situation in Malaysia, globally, and some other countries. It outlines the phases and movement control orders Malaysia implemented. Current statistics in Malaysia show over 8,500 total cases. New clusters were detected during the recovery movement control order phase. The document also discusses the increasing numbers seen in the United States, India, Brazil, Indonesia, and Singapore. It concludes by emphasizing the importance of following safety procedures until a vaccine is developed.
CDC dec 2015 - Strengthening a Culture of Laboratory SafetyMark Lacic
The document discusses the history and evolution of laboratory science and safety standards at the Centers for Disease Control and Prevention (CDC). It describes how CDC laboratories have grown from focusing on malaria and communicable diseases to encompassing over 150 laboratory groups conducting research on infectious diseases, environmental health, and more. It summarizes changes made at CDC in response to safety incidents in 2014, including establishing new laboratory leadership and revising risk assessment processes.
The coronavirus pandemic of 2019–2020 is an infectious disease caused by extreme acute respiratory coronavirus syndrome 2 (SARS‐CoV‐2). The virus primarily spread among people when they closely meet each other. Due to the decreased immune-compromised state, cancer patients are at high risk. Through this whitepaper, we have enlighted about the effect of the COVID-19 on cancer patients.
Paul E. Sax, MD prepared useful Practice Aids pertaining to COVID-19 for this CME/MOC/CNE/CPE activity titled "Coronavirus Disease 2019 (COVID-19): Need-to-Know Information and Practical Guidance for Healthcare Professionals on the Front Lines of Patient Care." For the full presentation, monograph, complete CME/MOC/CNE/CPE information, and to apply for credit, please visit us at https://bit.ly/3gBvfOw. CME/MOC/CNE/CPE credit will be available until July 23, 2021.
This bulletin is a publication of the CRC networks in Perak (Hospital Raja Permaisuri Bainun Ipoh, Hospital Seri Manjung and Hospital Taiping).
This issue emcompasses various research articles written by CRC staff, a research scope write-up to emphasize on the research focus this coming year, programmes conducted in 2021 as well as upcoming events across the CRC Perak Network this year.
(e-ISSN Number: 2682-7867).
Mass general covid 19 treatment guideline july012020Adiel Ojeda
This document provides guidance for clinicians at Massachusetts General Hospital (MGH) on the treatment of COVID-19. It summarizes recommended diagnostic testing and risk stratification for hospitalized patients. It also provides guidance on therapeutic considerations, including anti-infectives, cardiovascular medications, antithrombotics, and COVID-19 specific treatments such as remdesivir. The document is regularly updated as new data emerges on the management of COVID-19.
This document summarizes information from Dr. Tahseen J. Siddiqui on COVID-19. It discusses the three known coronaviruses that cause SARS, MERS, and COVID-19. It emphasizes that mitigation through strict social isolation is the best current strategy to slow transmission rates and prevent healthcare systems from being overwhelmed. The risks of personal infection are low but systemic risks are high if many require critical care simultaneously. Early action through testing, contact tracing, and quarantines have helped countries like Taiwan better control the spread.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
This document provides an overview of COVID-19 including its timeline, transmission, presentation, epidemiology, prevention, and containment plan. It discusses that COVID-19 is a respiratory infection caused by SARS-CoV-2. It outlines the timeline of the outbreak beginning in December 2019 in Wuhan, China. It also discusses transmission modes, signs and symptoms, disease progression, prevention strategies like isolation, quarantine, hand hygiene, and use of personal protective equipment.
This document provides information on the 2019 novel coronavirus (COVID-19) outbreak, including that it originated from Wuhan, China in December 2019 and is transmitted between humans. It causes respiratory illness with common symptoms like fever, cough and fatigue. While most cases are mild, management involves early detection, infection control measures, and supportive care like oxygen therapy for severe cases.
buy carestart covid-19 Antigen test by bio Access Inc, EUA Approvel Letter by...HK HuZef
The document provides instructions for using the CareStart COVID-19 Antigen rapid diagnostic test. It is a lateral flow test intended to qualitatively detect SARS-CoV-2 nucleocapsid protein antigen in nasopharyngeal swabs. The test involves extracting the swab in buffer, adding drops of extracted sample to the test cassette, and reading results at 10 minutes. Positive results require lines in both the test and control lines, while negative results have only a control line.
Dr Jennifer Njenga from Canada Home Care Group spent an hour teaching and educating us on the topic Vaccines and You. She covered myths about the vaccines and why you must take the second dose.
Researchers at the Network Dynamics and Simulation Science Laboratory have been using a combination of modeling techniques to predict the spread of the Ebola outbreak.
At Malayali Kerala Spa Ajman, Full Service includes individualized care for every client. We specifically design each massage session for the individual needs of the client. Our therapists are always willing to adjust the treatments based on the client's instruction and feedback. This guarantees that every client receives the treatment they expect.
By offering a variety of massage services, our Ajman Spa Massage Center can tackle physical, mental, and emotional illnesses. In addition, efficient identification of specific health conditions and designing treatment plans accordingly can significantly enhance the quality of massaging.
At Malayali Kerala Spa Ajman, we firmly believe that everyone should have the option to experience top-quality massage services regularly. To achieve that goal we offer cheap massage services in Ajman.
If you are interested in experiencing transformative massage treatment at Malayali Kerala Spa Ajman, you can use our Ajman Massage Center WhatsApp Number to schedule your next massage session.
Contact @ +971 529818279
Visit @ https://malayalikeralaspaajman.com/
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVedanta A
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...rightmanforbloodline
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - 34.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
English Drug and Alcohol Commissioners June 2024.pptxMatSouthwell1
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
End-tidal carbon dioxide (ETCO2) is the level of carbon dioxide that is released at the end of an exhaled breath. ETCO2 levels reflect the adequacy with which carbon dioxide (CO2) is carried in the blood back to the lungs and exhaled.
Non-invasive methods for ETCO2 measurement include capnometry and capnography. Capnometry provides a numerical value for ETCO2. In contrast, capnography delivers a more comprehensive measurement that is displayed in both graphical (waveform) and numerical form.
Sidestream devices can monitor both intubated and non-intubated patients, while mainstream devices are most often limited to intubated patients.
Management of Post Operative Pain: to make doctors conscious about the benefi...
COVID-19 Situationer #623.pdf
1. Issue 623 | January 10, 2022
Beat COVID-19 Today
A COVID-19 Philippine Situationer
Top regions by Active Cases
128,114
Active Cases as of 9 January 2022
(net of recoveries and deaths)
+26,113
Top Regions by New Cases
Note. Data on healthcare workers affected by COVID-19, testing capacity by laboratory, equipment utilization, and LIGTAS COVID facilities will be
included in the full situational report every Sunday.
A patient with an RT-PCR
confirmed case of COVID-19
without symptoms.
Breakdown of Active Cases
4,213
3.3%
Asymptomatic
119,276
93.1%
Mild
1,465
1.1%
Severe
A patient with mild symptoms
and stable vital signs. Unless
the patient belongs to high-risk
subgroups or has
comorbidities, they are often
not admitted to a treatment
facility.
A patient with clinical
signs of severe
pneumonia or severe
acute respiratory
infection
A patient with impending or
ongoing respiratory failure,
in need of mechanical
ventilation, or with evidence
of end-organ damage or with
septic shock.
Note. A person who is classified as having a mild case of COVID-19 but is considered high-risk due to age or the presence of comorbidities may be admitted to a
treatment facility. Moderate, severe or critical cases must be admitted to a health facility, regardless of inclusion in high-risk subgroups or presence of comorbidities.
Non-severe pneumonia: fever, cough, dyspnea or respiratory rate of 21-30 breaths/minute, oxygen saturation more than 92% at room air for adults, and cough or difficulty in breathing and
fast breathing or chest indrawing for children
Severe pneumonia: fever, cough, dyspnea or respiratory rate of more than 30 breaths/minute, oxygen saturation less than or equal to 92% at room air for adults, central cyanosis, oxygen
saturation less than 90%, fast breathing, very severe chest indrawing for children
2,851
2.2%
Moderate
A patient with clinical
signs of non-severe
pneumonia
309
0.2%
Critical
Total Cases as of 9 January 2022
2,965,447
+28,707
Recovered Died
2,785,183 52,150
+2,579 +15
NCR 16,924
Region IV-A: CALABARZON 5,858
Region III: Central Luzon 2,849
Region V: Bicol Region 430
Region VI: Western Visayas 413
Region I: Ilocos Region 384
Region II: Cagayan Valley 338
Region VII: Central Visayas 245
Region XI: Davao Region 169
Region VIII: Eastern Visayas 168
NCR 79,691
Region IV-A: CALABARZON 23,987
Region III: Central Luzon 10,975
Region VI: Western Visayas 1,580
Region I: Ilocos Region 1,552
Region II: Cagayan Valley 1,436
Region VII: Central Visayas 1,435
Region V: Bicol Region 1,232
Region XI: Davao Region 907
CAR 895
2. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
Notes.
1. Bars with dark green colors indicate the actual date of onset or date of death for newly-reported cases.
2. The cases from the “NCR” graph have been separated from cases of the “Luzon” graph.
3. Owing to delays in reporting, case counts within the gray area are still incomplete. Hence, we urge caution in interpreting data beyond this
14-day cutoff. Rest assured that the DOH continues to work tirelessly to ensure the timely reporting of accurate data.
2
CONFIRMED CASES BY DATE OF ONSET OF ILLNESS (NATIONWIDE)
Notes.
1. Bars with dark green colors indicate the actual date of onset or date of death for newly-reported cases.
2. In cases where date of onset of illness is unreported, date of specimen collection was used as proxy. Cases that do not have both are not
accounted for in the date of onset histogram. As of this situation report, around 10% of cases have unreported dates of specimen collection and
onset of illness.
3. Owing to delays in reporting, case counts within the gray area are still incomplete. Hence, we urge caution in interpreting data beyond this
14-day cutoff. Rest assured that the DOH continues to work tirelessly to ensure the timely reporting of accurate data.
CONFIRMED CASES BY DATE OF ONSET OF ILLNESS (DISAGGREGATED)
Visayas
Rest of Luzon
NCR
Mindanao
CONFIRMED DEATHS BY DATE OF DEATH (NATIONWIDE)
3. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
Cumulative Testing Output
3
Note. The number of confirmed severe and critical cases may not necessarily correspond to occupancy of ICU beds and mechanical ventilators as suspect and
probable cases in severe or critical condition also utilize these resources. Facilities which did not submit a daily utilization report have their most recent carry over to
today.
DAILY TESTING STATISTICS (Data for January 9, reported as of January 10, 2022 6 PM)
40%
14,675 beds occupied out of 36,355 as of 9 January 2022
41%
7,849 isolation
beds occupied
out of 19,488
Notes.
1. The DOH is continuously validating the number of positive individuals as reported by the laboratories. When necessary, they are deduplicated. As such, the
discrepancy with the number of confirmed cases does not necessarily reflect backlogs in case validation.
2. Please visit www.doh.gov.ph/covid19tracker for details regarding the testing output per laboratory.
3. A 6 PM cut-off for the situation report is used, and so the numbers presented here are not yet final. A few laboratories submit data between 6 PM and the time the
public data drop is generated.
UTILIZATION OF COVID-19 BEDS
Daily Positivity Rate
Daily Testing Output (Nationwide)
Samples Tested 60,755
Individuals Tested 55,394
Positive Tests 24,377
Positivity Rate 44.01%
Testing Backlog 2,359
Compliance of Labs 252/312
As of January 9, 2022
Samples tested 25,833,069
Individuals Tested 24,297,953
Positive Tests 3,230,728
Positivity Rate 13.3%
As of January 9, 2022
Testing Output (January 9)
COVID-19ʼS CAPACITY TO SPREAD (Rt
VALUE)
The time-varying reproduction number (Rt
) indicates the possible number of people being
infected by a sick person, at a specific time with control measures in place.
IMPORTANT NOTE. The reproduction number is measured using symptom onset, we do not include in the interpretation the past
14-16 days given the time between symptoms, health seeking, testing, and reporting. When interpreting the reproduction number
keep in mind that it is a lagging indicator (that is, it provides a snapshot of the situation two weeks ago). Please do not expect
this number to change daily.
● The reproduction number (Rt
) was around 2 early on in the outbreak. This meant that each confirmed
person with COVID was infecting 2 other people.
● Based on the latest data, we are 95 percent confident that Rt
= 2.745 ± 0.02, which means each infected
individual was infecting an average of 2.745 other persons around two weeks ago.
● Lowering this value is made possible though efforts such as social distancing, wearing of PPE, and
other means to stop the spread of the virus.
● The goal is for Rt
to be less than 1, which would mean that, on average, an infected person is infecting
less than one person, eventually stopping the transmission of COVID-19.
December 24: 2.592 ± 0.02
December 25: 2.745 ± 0.02
38%
1,306 ICU beds
occupied out of
3,403
41%
5,475 ward
beds occupied
out of 13,464
4. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
NAME OF HEALTH FACILITY OR LABORATORY REGION
1 A Star Laboratories, Inc.
NCR
2 Al Molecular Diagnostic Laboratory
3 Allied Care Expert - Valenzuela
4 Amang Rodriguez Memorial Hospital
5 Army General Hospital Molecular Laboratory
6 Asian Hospital & Medical Center
7 Ateneo Molecular Pathology Laboratory
8 Best Diagnostic Corporation
9 Be Safe MD, Inc.
10 BioPath Clinical Diagnostic, Inc.
11 Biopath Clinical Diagnostics Inc. (E. Rodriguez)
12 Caloocan City North Medical Center
13 Cardinal Santos Medical Center
14 Chinese Gen. Hospital
15 De Los Santos Medical Center
16 Detoxicare Molecular Diagnostics Laboratory
17 Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium (TALA)
18 East Avenue Medical Center
19 El Roi Molecular Diagnostic Laboratory
20 Ermita Molecular Diagnostic Laboratory, Inc.
21 F.Y. Manalo Medical Foundation, Inc. (formerly New Era Hospital)
22 Fe del Mundo Medical center
23 First Aide Diagnostic Center
24 Health Delivery Systems
25 Health Metrics, Inc.
26 Healthway Medical
27 Heartland Medical and Diagnostic Center
28 Hero Laboratories
29 Hi-Precision Diagnostic Center
30 Interpharma Solutions Philippines, Inc.
31 Intramuros Molecular Laboratory
32 JT Cenica Medical Health System
33 Kairos Diagnostics Laboratory
34 Kaiser Medical Center Inc.
35 Las Pinas General Hospital and Satellite Trauma Center
36 Lifecore Biointegrative Inc.
37 Lung Center of the Philippines (LCP)
38 Makati Medical Center (HB)
39 Manila Diagnostic Center for OFW Inc.
40 Manila Doctors Hospital
41 Manila Healthtek Inc.
42 Marikina Molecular Diagnostic Laboratory
43 Marikina Valley Medical Center
44 Marilao Medical and Diagnostic Clinic, Inc.
45 Medical Center Manila, Inc.
46 Medical Center Parañaque, Inc.
47 Medical Center of Taguig City, Inc.
48 Metro North Medical Center and Hospital Inc.
49 National Kidney and Transplant Institute
50 New World Diagnostics Inc. Premium Medical Branch
51 Olayn Medical Laboratory, Inc
52 Ospital ng Muntinlupa
53 Ospital ng Paranaque District II
54 Pasig City Children's Hospital - Child's Hope
55 PCR MED Molecular Laboratory
56 Philipine Medical Diagnostic & Laboratory Center Corporation
57 Philippine Airport Diagnostic Laboratory
58 Philippine Children's Medical Center
4
232 78 19 100%
NO. OF LICENSED RT-PCR LABORATORIES NO. OF LICENSED GENEXPERT LABS TOTAL NO. OF LABORATORIES APPLYING FOR LICENSE* % APPLICATIONS AT STAGE 3 and 4*
STATUS OF LABORATORY LICENSING as of 9 January 2022
.
Licensed RT-PCR Laboratories
5. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
5
NAME OF HEALTH FACILITY OR LABORATORY REGION
59 Philippine Genome Center UP-Diliman (NHB)
60 Philippine National Police Crime Laboratory
NCR
61 Philippine Red Cross - National Blood Center
62 Philippine Red Cross - Port Area
63 PNP General Hospital
64 PRC - PRC Logistics and Multipurpose Center
65 PSG Station Hospital Molecular Laboratory
66 QR Medical Laboratories Inc. (VitaCare)
67 Quezon City Molecular Diagnostics Laboratory
68 Quirino Memorial Medical Center
69 Research Institute for Tropical Medicine, Inc. (RITM)
70 Safeguard DNA Diagnostics, Inc.
71 San Lazaro Hospital (SLH)
72 San Miguel Foundation Testing Laboratory
73 Singapore Diagnostic, Inc.
74 South Super Hi Way Molecular Diagnostic Lab
75 St. Luke's Medical Center - BGC (HB)
76 St. Luke's Medical Center- QC
77 Sta. Ana Hospital
78 Supercare Medical Services, Inc.
79 Taguig City Molecular Laboratory
80 The Lord's Grace Medical and Industrial Clinic
81 The Medical City - Ortigas
82 The Premier Molecular Diagnostics
83 Tropical Disease Foundation
84 Truhealth Diagnostics Center, Corp.
85 University of Perpetual Help System Dalta
86 University of the East Ramon Magsaysay Memorial Medical Center
87 UP National Institutes of Health (UP NIH)
88 UP-PGH-MRL
89 Valenzuela Hope Molecular Laboratory
90 Veteran Memorial Medical Center
91 Victoriano Luna Medical Center -AFRIMS - Collaborative Molecular Laboratory
92 Amai Pakpak Medical Center
BARMM
93 Philippine Red Cross Cotabato City - Maguindanao Molecular Laboratory
94 Baguio General Hospital and Medical Center (BGHMC)
CAR
95 Benguet General Hospital
96 Luis Hora Memorial Regional Hospital
97 Parkway Medical and Diagnostic Center
98 Tabuk City Covid-19 RT-PCR Testing Laboratory
99 Adela Serra TY Memorial Medical Center
CARAGA
100 Butuan Medical Center
101 Philippine Red Cross Molecular Laboratory
102 Democrito O. Plaza Memorial Hospital
103 Dagupan Doctors Villaflor Memorial Hospital
I
104 Ilocos Training Regional Medical Center
105 Mariano Marcos Memorial Hospital
106 Pangasinan Molecular Diagnostic Laboratory
107 Region 1 Medical Center
108 Metro Pangasinan Molecular Laboratory
109 Tayug Family Hospital
110 Marilao Medical and Diagnostic Clinic
Licensed RT-PCR Laboratories
6. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
6
NAME OF HEALTH FACILITY OR LABORATORY REGION
111 Cagayan Valley Medical Center Molecular Laboratory
II
112 Philippine Red Cross Isabela Molecular Laboratory
113 San Antonio City of Ilagan Hospital
114 Southern Isabela Medical Center
115 Bataan General Hospital
III
116 Bulacan Medical Center
117 Dr. Paulino J. Garcia Memorial Research and Medical Center
118 Graman Medical & Maternity Hospital Inc Molecular Laboratory
119 Green City Medical Center
120 Jose B. Lingad Memorial Hospital
121 Marilao Medical and Diagnostic Clinic, Inc.
122 Mariveles District Hospital
123 Multi-Lifecare Foundation Molecular Laboratory
124 Olongapo City Molecular and Diagnostic Laboratory
125 Our Lady of Mt. Carmel Medical Center Molecular Laboratory
126 Philippine Red Cross - Logistics and Training Center
127 Philippine Red Cross Clark Molecular Laboratory
128 Qualimed Hospital - San Jose Del Monte
129 Tarlac Provincial Hospital Molecular Laboratory
130 The Medical City Clark Inc.
131 Antipolo City Molecular Laboratory
IV-A
132 Batangas Medical Center
133 Calamba Medical Center
134 City of Dasmarinas Molecular Diagnostic Laboratory
135 Daniel O. Mercado Medical Center
136 De La Salle Medical and Health Sciences Institute
137 Fatima University Medical Center Antipolo Corp.
138 GentriMed Molecular Laboratory
139 Laguna City Provincial Hospital-San Pablo City District Hospital
140 Laguna Holy Family Hospital, Inc.
141 Laguna Holy Family Hospital, Inc - Satellite Molecular Laboratory
142 Lucena United Doctors Hospital and Medical Center
143 Mary Mediatrix Medical Center
144 Mauban Municipal Health Office Molecular Laboratory
145 Ospital ng Imus
146 Ospital ng Lipa
147 PRC- Batangas Chapter Molecular Laboratory
148 Qualimed Hospital Sta. Rosa
149 San Pablo College Medical Center
150 Soriano-Leyble Medical and Maternity Hospital
151 Stark Molecular Laboratory Inc.
152 The Medical City South Luzon
153 UPLB Covid-19 Molecular Laboratory
154 Breeze Medical Services
155 Puerto Princesa City Molecular Laboratory
IV-B
156 PHO Molecular Biology Laboratory
157 Bicol Medical Center
V
158 Bicol Region General Hospital and Geriatric Medical Center
159 Bicol Regional Diagnostic and Reference Laboratory
160 Naga City Molecular Laboratory
161 Metro Health Specialist Hospital
162 Antique Bio-Molecular Laboratory
VI
163 Bacolod Queen of Mercy Hospital
164 Corazon Locsin Montelibano Memorial Regional Hospital
165 Dr. Pablo O. Torre Memorial Hospital
166 Dr. Rafael S. Tumbokon Memorial Hospital
167 Iloilo Provincial Hospital
Licensed RT-PCR Laboratories
7. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
7
Licensed RT-PCR Laboratories
NAME OF HEALTH FACILITY OR LABORATORY REGION
168 Metro Iloilo Hospital and Medical Center
VI
169 Next Gen PCR Diagnostic Laboratory
170 Philippine Red Cross Passi City Molecular Laboratory
171 PRC - Negros Occidental Molecular Laboratory
172 Qualimed Health Network - Iloilo
173 Roxas City Diagnostic and Laboratory Center
174 Roxas Memorial Provincial Hospital Molecular Laboratory
175 Uswag Iloilo Molecular Laboratory
176 Western Visayas Medical Center (WVMC)
177 Teresita Jalandoni Provincial Hospital
178 Western Visayas State University Medical Center
179 Tomboc-Salayog Hospital
180 Safeguard DNA Diagnostics, Inc.
181 Allegiant Regional Care Hospital
VII
182 BioPath Clinical Diagnostic, Inc. - AFRIMS PCR laboratory
183 BioPath Clinical Diagnostic, Inc. - CEBU
184 Bohol Containerized PCR Laboratory
185 Cebu Doctors University Hospital, Inc.
186 Cebu TB Reference Laboratory
187 Chong Hua Hospital
188 Governor Celestino Gallares Memorial Medical Center
189 Negros Oriental Provincial Hospital
190 Perpetual Succour Hospital of Cebu, Inc.
191 Philippine Red Cross - Cebu Chapter
192 Prime Care Alpha Covid-19 Testing Laboratory
193 RHS 7 Molecular Laboratory (PNP)
194 University of Cebu Medical Center
195 Vicente Sotto Memorial Medical Center (VSMMC)
196 Divine Word Hospital
VIII
197 Eastern Visayas Regional Covid-19 Testing Center
198 OSPA - Farmersʼ Medical Center
199 Salvacion Oppus Yniguez Memorial Provincial Hospital
200 Ciudad Medical Zamboanga
IX
201 Philippine Red Cross - Molecular Biology Laboratory
202 Zamboanga City Medical Center-Department of Agriculture Satellite Laboratory for COVID-19 Testing
203 Zamboanga del Norte Medical Center
204 Zamboanga Del Sur Medical Center
205 Dr. Jose Rizal Memorial Hospital
206 Lanao Del Norte Covid-19 Testing Laboratory
X
207 Gregorio T. Lluch Memorial Hospital
208 Maria Reyna Xavier University Hospital Inc.
209 Mayor Hilarion A. Ramiro Sr. Medical Center
210 Misamis Occidental RT-PCR Laboratory
211 Northern Mindanao Medical Center
212 Northern Mindanao Medical Center- Satellite Covid-19 Laboratory
213 Philippine Red Cross - Cagayan de Oro Chapter
214 Polymedic Medical Plaza
215 Bukidnon Provincial Medical Center
216 APEX Mining CO. Inc.
XI
217 Brokenshire Integrated Health Ministries, Inc.
218 Davao de Oro Provincial Hospital
219 Davao International Airport Laboratory
220 Davao One World Diagnostic Center Incorporated
8. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
8
Licensed RT-PCR Laboratories
NAME OF HEALTH FACILITY OR LABORATORY REGION
221 Davao Regional Medical Center
XI
222 Los Amigos Davao Laboratory
223 PRO 11 RT- PCR Molecular Laboratory
224 Safeguard DNA Diagnostics, Inc.
225 Southern Philippines Medical Center (SPMC)
226 Southern Philippines Medical Center (SPMC) - Pop-up
227 Vitalab Molecular Laboratory
228 Cotabato Regional Medical Center
XII
229 Dr. Jorge P. Royeca Hospital
230 Mlang District Hospital
231 St. Louis Molecular Diagnostic Laboratory
232 Tomboc-Salayog Hospital
9. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
Licensed Cartridge-based PCR or GeneXpert Laboratories
NAME OF HEALTH FACILITY OR LABORATORY REGION
1 Amai Pakpak Medical Center BARMM
2 Al Molecular Diagnostic Laboratory
NCR
3 Amang Rodriguez Memorial Center
4 Amosup Seamenʼs Hospital
5 BioPath Clinical Diagnostic, Inc.
6 BioPath Clinical Diagnostic, Inc. (E. Rodriguez)
7 Cardinal Santos Medical Center
8 Chinese Gen. Hospital
9 Dr. Jose B. Rodriguez Memorial Hospital and Sanitarium (TALA)
10 El Roi Medical Clinic and Diagnostic Center
11 Hi-Precision Diagnostic Center
12 IOM- Manila Health Centre Laboratory
13 Jose R. Reyes Memorial Medical Center
14 Kairos Diagnostics Laboratory
15 Las Pinas General Hospital and Satellite Trauma Center
16 Lung Center of the Philippines
17 National Kidney and Transplant Institute
18 National Childrenʼs Hospital
19 New World Diagnostics Inc. Premium Medical Branch
20 Olayn Medical Laboratory, Inc
21 Philippine Airport Diagnostic Laboratory
22 Philippine General Hospital
23 Philippine Heart Center
24 Rizal Medical Center
25 St. Lukeʼs Medical Center - BGC
26 St. Lukeʼs Medical Center - QC
27 Sta. Ana Hospital - Closed System Molecular Laboratory
28 The Medical City - Ortigas
29 Tondo Medical Center
30 Victoriano Luna Medical Center -AFRIMS - Collaborative Molecular Laboratory
31 Dr. Jose Fabella Memorial Hospital
32 Medical Center Manila, Inc
33 Bureau of Quarantine
33 Medical Center of Paranaque
34 Detoxicare Molecular Diagnostics Laboratory
35 Ilocos Training Regional Medical Center
I
36 Mariano Marcos Memorial Hospital
37 Region 1 Medical Center
38 Cagayan Valley CHD TB Reference Laboratory II
39 Bataan General Hospital
III
40 Bulacan Medical Center
41 Central Luzon Doctor's Hospital
42 Jose B. Lingad Memorial Hospital
43 Mariveles District Hospital
44 President Ramon Magsaysay Provincial Hospital
45 Skyline Hospital and Medical Center
46 Tarlac Provincial Hospital
47 Pampanga Medical Specialist Hospital
48 Rakkk Prophet Medical Center, Inc.
IV-A
49 Batangas Medical Center
50 First Cabuyao Hospital and Medical Center, Inc.
51 GentriMedical Center and Hospital, Inc.
52 Mabini Community Hospital
10. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
Licensed Cartridge-based PCR or GeneXpert Laboratories
10
NAME OF HEALTH FACILITY OR LABORATORY REGION
53 RAKKK Prophet Medical Center, Inc.
IV-A
54 Sta. Rosa CHO
55 Culion Sanitarium and General Hospital
IV-B
56 Occidental Mindoro Provincial Hospital
57 Oriental Mindoro Provincial Hospital
58 Ospital ng Palawan
59
Puerto Galera Molecular Laboratory (Formerly Best Care Medical Clinic & Diagnostic Center,
Inc.)
60 Bicol Medical Center V
61 Next Gen PCR Diagnostic Laboratory VI
62 BioPath Clinical Diagnostic, Inc. - AFRIMS
VII
63 Cebu Doctors University Hospital, Inc.
54 Cebu TB Reference Laboratory
65 Chong Hua Hospital
66 Perpetual Succour Hospital of Cebu, Inc.
67 Siliman University Medical Foundation
68 West Metro Medical Center
IX
69 Zamboanga City Medical Center
70 Northern Mindanao Medical Center X
71 Davao Doctors Hospital
XI
72 Davao Regional Medical Center
73 Cotabato Regional Medical Center
XII
74 Dr. Arturo Pingoy Medical Center
75 St. Elizabeth Hospital
76 Butuan Medical Center
CARAGA
77 CARAGA Regional Hospital
78 Manuel J. Santos Hospital
11. COVID-19 PHILIPPINE SITUATIONER #623 (JANUARY 10, 2022)
11
Contact Details
For further information, you
may reach us through the
following platforms:
SOCIAL MEDIA ACCOUNTS
Facebook:
fb.com/OfficialDOHgov
Twitter:
@DOHgovph
Viber:
DOH PH COVID-19
TikTok:
@dohgovph
WEBSITES
DOH:
www.doh.gov.ph
Healthy Pilipinas:
healthypilipinas.ph
CONTACT NUMBERS
(02) 894 - COVID (26843) or
1555 (for all subscribers)
THANK YOU for checking out
this issue of Beat-COVID-19
Today! Weʼd like to know what
you think. Send us your
feedback at
dohfeedback@gmail.com.
RECENT UPDATES ON COVID-19
As of January 9, 2022
● DOH recorded 128,114 active cases with the majority of the patients
exhibiting mild symptoms 119,276 (93.1%) while 309 (0.2%)
patients are in critical condition.
● DOH recorded 29,609 health care workers positive for COVID-19. Of
these, 28,723 (97.0%) have recovered, 117 (0.4%) have died and 769
(2.6%) were active cases. Of these active cases, 581 (75.6%) were
mild cases, 167 (21.7%) were asymptomatic, 9 (1.2%) in severe
condition, 2 (0.3%) in critical condition, and 10 (1.3%) in moderate
condition.
● A total of 2,056,010 Returning Overseas Filipinos (ROFs) have
arrived in the country (Land-based: 1,987,625; Sea-based: 68,385).
Among the ROFs, 26,092 were confirmed COVID-19 patients
(Land-based: 16,438; Sea-based: 9,654). Among these, 904 are
currently admitted, 25,160 have already recovered; and 28 have died.